Literature DB >> 25646889

Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation.

Hai Li1, Qiang Xia2, Bo Zeng3, Shu-Ting Li3, Heng Liu4, Qi Li5, Jun Li6, Shu-Yin Yang3, Xiao-Jun Dong3, Ting Gao3, Stefan Munker5, Yan Liu5, Roman Liebe7, Feng Xue2, Qi-Gen Li2, Xiao-Song Chen2, Qiang Liu8, Hui Zeng9, Ji-Yao Wang10, Qing Xie11, Qin-Hua Meng12, Jie-Fei Wang13, Peter R Mertens14, Frank Lammert15, Manfred V Singer5, Steven Dooley5, Matthias P A Ebert5, De-Kai Qiu3, Tai-Ling Wang16, Hong-Lei Weng17.   

Abstract

BACKGROUND & AIMS: Distinguishing between acute on chronic liver failure (ACLF) and decompensated liver cirrhosis is difficult due to a lack of pathological evidence.
METHODS: A prospective single-center study investigated 174 patients undergoing liver transplantation due to acute decompensation of hepatitis B virus (HBV)-associated liver cirrhosis. Two groups were distinguished by the presence or absence of submassive hepatic necrosis (SMHN, defined as necrosis of 15-90% of the entire liver on explant). Core clinical features of ACLF were compared between these groups. Disease severity scoring systems were applied to describe liver function and organ failure. Serum cytokine profile assays, gene expression microarrays and immunohistochemical analyzes were used to study systemic and local inflammatory responses.
RESULTS: SMHN was identified in 69 of 174 patients proven to have cirrhosis by histological means. Characteristic features of SMHN were extensive necrosis along terminal hepatic veins and spanning multiple adjacent cirrhotic nodules accompanied by various degrees of liver progenitor cell-derived regeneration, cholestasis, and ductular bilirubinostasis. Patients with SMHN presented with more severely impaired hepatic function, a higher prevalence of multiple organ failure (as indicated by higher CLIF-SOFA and SOFA scores) and a shorter interval between acute decompensation and liver transplantation than those without SMHN (p<0.01 for all parameters). Further analyzes based on serum cytokine profile assays, gene expression microarrays and immunohistochemical analyzes revealed higher levels of anti-inflammatory cytokines in patients with SMHN.
CONCLUSIONS: SMHN is a critical histological feature of HBV-associated ACLF. Identification of a characteristic pathological feature strongly supports that ACLF is a separate entity in end-stage liver disease.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute decompensation; Acute-on-chronic liver failure; Cirrhosis; HBV; Liver histology; Submassive hepatic necrosis

Mesh:

Substances:

Year:  2015        PMID: 25646889     DOI: 10.1016/j.jhep.2015.01.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  23 in total

1.  Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine Expression.

Authors:  Zhe Shen; Yan Liu; Bedair Dewidar; Junhao Hu; Ogyi Park; Teng Feng; Chengfu Xu; Chaohui Yu; Qi Li; Christoph Meyer; Iryna Ilkavets; Alexandra Müller; Carolin Stump-Guthier; Stefan Munker; Roman Liebe; Vincent Zimmer; Frank Lammert; Peter R Mertens; Hai Li; Peter Ten Dijke; Hellmut G Augustin; Jun Li; Bin Gao; Matthias P Ebert; Steven Dooley; Youming Li; Hong-Lei Weng
Journal:  Am J Pathol       Date:  2016-05-10       Impact factor: 4.307

Review 2.  Management of acute-on-chronic liver failure: an algorithmic approach.

Authors:  Shiv Kumar Sarin; Ashok Choudhury
Journal:  Hepatol Int       Date:  2018-08-16       Impact factor: 6.047

3.  Down-regulated cylindromatosis enhances NF-κB activation and aggravates inflammation in HBV-ACLF patients.

Authors:  Xueyun Zhang; Yao Zhang; Pu Zhou; Jingwen Ai; Xiaoqin Liu; Quanbao Zhang; Zhengxin Wang; Hongyan Wang; Wenhong Zhang; Jiming Zhang; Yuxian Huang
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

Review 4.  Overview on acute-on-chronic liver failure.

Authors:  Jing Zhang; Shan Gao; Zhongping Duan; Ke-Qin Hu
Journal:  Front Med       Date:  2016-03-14       Impact factor: 4.592

Review 5.  Acute-on-chronic liver failure: terminology, mechanisms and management.

Authors:  Shiv K Sarin; Ashok Choudhury
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-03       Impact factor: 46.802

Review 6.  Two sides of one coin: massive hepatic necrosis and progenitor cell-mediated regeneration in acute liver failure.

Authors:  Hong-Lei Weng; Xiaobo Cai; Xiaodong Yuan; Roman Liebe; Steven Dooley; Hai Li; Tai-Ling Wang
Journal:  Front Physiol       Date:  2015-06-16       Impact factor: 4.566

7.  Human umbilical cord-derived mesenchymal stem cells improve the function of liver in rats with acute-on-chronic liver failure via downregulating Notch and Stat1/Stat3 signaling.

Authors:  Yulin He; Xingrong Guo; Tingyu Lan; Jianbo Xia; Jinsong Wang; Bei Li; Chunyan Peng; Yue Chen; Xiang Hu; Zhongji Meng
Journal:  Stem Cell Res Ther       Date:  2021-07-13       Impact factor: 6.832

8.  Low Growth Hormone Levels Predict Poor Outcome of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.

Authors:  Daxian Wu; Lingjian Zhang; Shanshan Ma; Yalei Zhao; Ronggao Chen; Fen Zhang; Qiuhong Liu; Xiaowei Xu; Zhongyang Xie
Journal:  Front Med (Lausanne)       Date:  2021-07-06

Review 9.  Acute-on-chronic liver failure: a new syndrome in cirrhosis.

Authors:  Richard Moreau
Journal:  Clin Mol Hepatol       Date:  2016-03-28

10.  Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis.

Authors:  Mark J W McPhail; Debbie L Shawcross; Matthew R Lewis; Iona Coltart; Elizabeth J Want; Charalambos G Antoniades; Kiril Veselkov; Evangelos Triantafyllou; Vishal Patel; Oltin Pop; Maria Gomez-Romero; Michael Kyriakides; Rabiya Zia; Robin D Abeles; Mary M E Crossey; Wayel Jassem; John O'Grady; Nigel Heaton; Georg Auzinger; William Bernal; Alberto Quaglia; Muireann Coen; Jeremy K Nicholson; Julia A Wendon; Elaine Holmes; Simon D Taylor-Robinson
Journal:  J Hepatol       Date:  2016-01-18       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.